Blue Wave: What Really Supports Copter's Carrying Value
Copter now carries almost the entire core value story for Blue Wave, but the NIS 1.676 million carrying amount rests mainly on goodwill, an intangible asset, and future rights. As long as there are no customers, no backlog, and no active commercial setup, this is still more accounting value than accessible value.
What This Follow-up Is Isolating
The main article argued that Blue Wave's return to positive equity rests almost entirely on Copter. This follow-up isolates one narrower question: what really supports the carrying value of the Copter investment, and how much of that value already looks like a real economic base that common shareholders can actually access.
The short answer is sharp. The carrying value exists, but it still does not rest on positive net assets or an active customer base. At the end of 2025 the Copter investment was carried at NIS 1.676 million. Of that, Blue Wave's share of Copter's net assets was negative NIS 106 thousand. What supports the balance is NIS 1.377 million of goodwill and NIS 405 thousand of intangible assets.
That does not make the value fictitious. It does mean that, for now, this is mostly the value of technology, rights, and commercialization optionality, not value already backed by a clean balance sheet, recurring customers, or backlog. For shareholders, that distinction matters: value can be created before it becomes accessible.
The Carrying-Value Bridge
The number that helped pull Blue Wave's equity back into positive territory is not a positive share of Copter's net assets. It is the opposite. Blue Wave's share of net assets is already negative. What holds the investment at NIS 1.676 million are the goodwill and intangible asset recognized through the purchase-price-allocation process.
That chart is the center of gravity here. It shows that the accounting anchor is not currently built on an excess of assets over liabilities. It is built on a layer of value that assumes the technology and the rights accumulated in Copter will later translate into commercialization. Even after the purchase-price allocation was completed, the picture did not converge toward positive net assets. It simply became clearer.
At the same time, Copter did post NIS 224 thousand of revenue in 2025, but also NIS 1.539 million of expenses and a NIS 1.315 million loss. So the carrying value does not sit on a company that is already producing operating profitability. It sits on a much earlier stage: technology that has moved forward, but has not yet reached stable product economics.
Revenue Exists, The Commercial Base Still Does Not
The most interesting gap is not between revenue and loss. It is between the mere existence of revenue and the way the activity is still described. The same filing says there are no customers, no order backlog, no active marketing and distribution setup, and no expectation of sales in the near term. Production capacity is also described as individual products made with the help of external suppliers for pilots, alongside an assembly line that can meet only current needs.
That is the heart of the story. NIS 224 thousand of revenue is not being framed here as the start of a broad sales engine. It is also not accompanied by customers, orders, or an active commercial infrastructure that would allow the reader to lean on it as a recurring base. In other words, there is operational proof of life, but the filing still places Copter in a development, testing, and product-adjustment stage.
| Layer | What already exists | What still does not | Why it matters |
|---|---|---|---|
| 2025 results | NIS 224 thousand of revenue | Profitability or commercial scale | Revenue alone does not prove commercialization |
| Customers | Pilot activity | Actual customers | There is still no demand base that can be measured |
| Marketing and distribution | Contractual distribution rights | An active sales and distribution setup | The right exists, the channel is not yet built |
| Backlog | Technology progress | Order backlog | There is still no visibility into near-term revenue |
| Production | Individual products and an assembly line for current needs | Broader manufacturing setup | It is still hard to turn rights and milestones into scaled deliveries |
This table explains why the NIS 224 thousand number has to be read carefully. If there were already a formed commercial thesis here, you would expect to see at least one of the following: customers, backlog, a sales setup, or a production description ready for broader scale. Right now, none of those anchors has appeared yet.
Blue Wave's Rights Are Stronger Than The Economics Already Proven
On the other hand, it would also be wrong to dismiss what Blue Wave has actually secured. After completion of milestone two, it holds a board seat at Copter, veto rights on material matters, information rights, a right of first refusal, tag-along rights, anti-dilution protection, and, subject to the relevant diluted holding threshold, signing rights at Copter. On the commercial side, it has worldwide exclusivity for mikvah water purifiers, exclusivity in Israel, Asia, and Africa for hydroponics, and distribution rights in swimming-pool water treatment.
The fact that the distribution agreement remains in force even without continued investment after milestone two also strengthens Blue Wave's standing inside the deal. That explains why this is not just a passive minority stake in a startup. There is partial control over direction, access to information, and commercial rights that could become valuable if the product reaches commercialization.
But discipline matters here as well. Rights are not the same thing as accessible value. Those rights are still subject to annual sales milestones, Blue Wave committed to minimum annual purchases of Copter products, and the future milestones tied to completion of the PRD, delivery of 500 units, and then delivery of another 1,000 units have not yet been completed. As of the approval date of the financial statements, none of those future milestones had been completed.
What This Means For Shareholders
The right way to read Copter is to separate three layers. There is an accounting layer: goodwill and an intangible asset. There is an operating layer: technology, pilots, and early revenue. And there is a legal and commercial layer: investment rights, governance rights, and distribution rights. All three layers help explain why the investment is carried at a meaningful value. What is still missing is a value-capture layer.
Value capture would look different. It would include a customer base, backlog, an active go-to-market setup, or at least a production path capable of supporting broader sales. As long as those are absent, the NIS 1.676 million should be read more as the carrying value of a commercialization option than as an asset comparable to cash, near-term distributable value, or defendable positive net assets.
That is also why Copter is both the center of the thesis and the center of the risk. It is the asset supporting Blue Wave's balance sheet today, but it also shows how little of that value is already accessible to shareholders in a practical sense. If the PRD is completed, if customers appear, and if production capacity moves from pilot mode into commercial mode, the carrying value will look much easier to defend. Until then, it remains more a value of promise than a value of proof.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.